Sangamo Therapeutics, Inc
isaralgagene civaparvovec
Fabry disease
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews isaralgagene civaparvovec for Fabry disease around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“Isaralgagene civaparvovec has a clear pathway to accelerated approval from the FDA, using mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study. The FDA has recently affirmed to”